@article {WANG6981, author = {ZHI-QIANG WANG and CASEY L. JOHNSON and AMIT KUMAR and DAVID P. MOLKENTINE and JESSICA M. MOLKENTINE and TATIANA RABIN and KATHRYN A. MASON and LUKA MILAS and UMA RAJU}, title = {Inhibition of P-TEFb by DRB Suppresses SIRT1/CK2α Pathway and Enhances Radiosensitivity of Human Cancer Cells}, volume = {34}, number = {12}, pages = {6981--6989}, year = {2014}, publisher = {International Institute of Anticancer Research}, abstract = {Background: Positive transcription elongation factor-b (P-TEFb) is a complex containing CDK9 and a cyclin (T1, T2 or K). The effect of inhibition of P-TEFb by 5,6-dichloro-l-β-D-ribofuranosyl benzimidazole (DRB) on cell radiosensitivity and the underlying mechanisms were investigated. Materials and Methods: Six human cancer cell lines were subjected to 3H-uridine incorporation, cell viability and clonogenic cell survival assays; cell-cycle redistribution and apoptosis assay; western blots and nuclear 53BP1 foci analysis after exposing the cells to DRB with/without γ-radiation. Results: DRB suppressed colony formation and enhanced radiosensitivity of all cell lines. DRB caused a further increase in radiation-induced apoptosis and cell-cycle redistribution depending on p53 status. DRB prolonged the presence of radiation-induced nuclear p53 binding protein-1 (53BP1) foci and suppressed the expression of sirtuin-1 (SIRT1) and casein kinase 2-alpha (CK2α), suggesting an inhibition of DNA repair processes. Conclusion: Our findings indicate that DRB has the potential to increase the efficacy of radiotherapy and warrants further investigation using in vivo tumor models.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/34/12/6981}, eprint = {https://ar.iiarjournals.org/content/34/12/6981.full.pdf}, journal = {Anticancer Research} }